Matthew G. Guenther, Ph.D.
Affiliations: | 2001 | University of Pennsylvania, Philadelphia, PA, United States |
Area:
Molecular Biology, GeneticsGoogle:
"Matthew Guenther"Parents
Sign in to add mentor| Mitchell A. Lazar | grad student | 2001 | Penn | |
| (Transcriptional repression by a core nuclear hormone receptor corepressor complex.) | ||||
| Richard A. Young | post-doc | 2002-2012 | (Neurotree) | |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Lambert AW, Fiore C, Chutake Y, et al. (2022) ΔNp63/p73 drive metastatic colonization by controlling a regenerative epithelial stem cell program in quasi-mesenchymal cancer stem cells. Developmental Cell. 57: 2714-2730.e8 |
| Lambert A, Fiore C, Chutake Y, et al. (2020) Abstract P4-04-02: Epigenomic analysis of cancer stem cells (CSCs) from triple-negative breast cancer (TNBC) reveals p63 and p73 as core metastasis drivers Cancer Research. 80 |
| Beaulieu ME, Jauset T, Massó-Vallés D, et al. (2019) Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy. Science Translational Medicine. 11 |
| Guenther M, Lambert A, Chen M, et al. (2018) Abstract P2-04-03: Epigenomic analysis of cancer stem cell (CSC)-enriched triple-negative breast cancer (TNBC) populations reveals gene regulatory circuitry and novel tumor cell vulnerabilities Cancer Research. 78 |
| Beaulieu M, Jauset T, Massó-Vallés D, et al. (2018) Abstract 3956: Omomyc-based cell-penetrating peptides: From proof of concept to a clinically viable anti-Myc therapy Cancer Research. 78: 3956-3956 |
| McKeown MR, Corces MR, Eaton ML, et al. (2017) Super-Enhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist. Cancer Discovery |
| Fiore CM, McKeown MR, Lee E, et al. (2017) Abstract PR05: SY-1425 (tamibarotene), a potent and selective RARα agonist, induces changes in the transcriptional regulatory circuit of AML cells leading to differentiation Clinical Cancer Research. 23 |
| McKeown, Fiore C, Lee E, et al. (2017) Abstract P6-11-18: A novel subgroup of estrogen receptor positive breast cancer may benefit from super-enhancer guided patient selection for retinoic acid receptor α agonist treatment Cancer Research. 77 |
| Beaulieu M, Jauset T, Massó-Vallés D, et al. (2017) Abstract 2167: Preclinical validation of an Omomyc cell-penetrating peptide as a viable anti-Myc therapy Cancer Research. 77: 2167-2167 |
| Orlando DA, McKeown MR, Chen MW, et al. (2015) Abstract A1-69: Predicting drug response by profiling the epigenome: Super-enhancers as biomarkers Cancer Research. 75 |